| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Authors' Affiliations: 1 Institute of Pharmacology and Institute of Pharmacy, University of Greifswald, Greifswald, Germany; Departments of 2 Medicine and 3 Cancer Biology and 4 Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee; and 5 Massachusetts General Hospital Cancer Center; 6 Department of Systems Biology, Harvard Medical School, Boston, Massachusetts
Requests for reprints: Carlos L. Arteaga, Division of Oncology/Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232-6307. Phone: 615-936-3524; Fax: 615-936-1790; E-mail: carlos.arteaga{at}vanderbilt.edu.
Purpose: We have investigated mechanisms of acquired resistance to the HER2 antibody trastuzumab in BT-474 human breast cancer cells.
Experimental Design: BT-474 xenografts established in athymic nude mice were eliminated by trastuzumab. Continuous cell lines (HR for Herceptin resistant) were generated from tumors that recurred in the presence of continuous antibody therapy.
Results: The isolated cells behaved resistant to trastuzumab in culture as well as when reinjected into nude mice. They retained HER2 gene amplification and trastuzumab binding and were exquisitely sensitive to peripheral blood mononuclear cells ex vivo in the presence of the antibody. The HR cells exhibited higher levels of phosphorylated epidermal growth factor receptor (EGFR) and EGFR/HER2 heterodimers. Phosphorylation of HER2 in HR cells was inhibited by the EGFR tyrosine kinase inhibitors erlotinib and gefitinib. Gefitinib also inhibited the basal association of p85 with phosphorylated HER3 in HR cells. Both inhibitors as well as the dual EGFR/HER2 inhibitor, lapatinib, induced apoptosis of the HR cells in culture. Growth of established HR5 xenografts was inhibited by erlotinib in vivo. In addition, the HR cells overexpressed EGFR, transforming growth factor 
, heparin-binding EGF, and heregulin RNAs compared with the parental trastuzumab-sensitive cells.
Conclusions: These results are consistent with the inability of trastuzumab to block the heterodimerization of HER2 and suggest that amplification of ligand-induced activation of ErbB receptors is a plausible mechanism of acquired resistance to trastuzumab that should be investigated in primary mammary cancers.
Commentary
Clin. Cancer Res. 2007 13: 4657-4659.
This article has been cited by other articles:
|
|
 |
|
  G. D. Lewis Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blattler, J. M. Lambert, R. V.J. Chari, R. J. Lutz, et al. Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate Cancer Res., November 15, 2008; 68(22): 9280 - 9290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Arteaga, A. O'Neill, S. L. Moulder, M. Pins, J. A. Sparano, G. W. Sledge, and N. E. Davidson A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6277 - 6283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Wang, B. Xiang, M. Guix, M. G. Olivares, J. Parker, C. H. Chung, A. Pandiella, and C. L. Arteaga Transforming Growth Factor {beta} Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab Mol. Cell. Biol., September 15, 2008; 28(18): 5605 - 5620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Costantini, K. Bateman, K. McLarty, K. A. Vallis, and R. M. Reilly Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electron-Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate J. Nucl. Med., September 1, 2008; 49(9): 1498 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Belkhiri, A. A. Dar, D. F. Peng, M. H. Razvi, C. Rinehart, C. L. Arteaga, and W. El-Rifai Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells Clin. Cancer Res., July 15, 2008; 14(14): 4564 - 4571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Rowe, T. Ozbay, L. M. Bender, and R. Nahta Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer Mol. Cancer Ther., July 1, 2008; 7(7): 1900 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. McGowan, E. McKiernan, F. Bolster, B. M. Ryan, A. D. K. Hill, E. W. McDermott, D. Evoy, N. O'Higgins, J. Crown, and M. J. Duffy ADAM-17 predicts adverse outcome in patients with breast cancer Ann. Onc., June 1, 2008; 19(6): 1075 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Contessa, M. S. Bhojani, H. H. Freeze, A. Rehemtulla, and T. S. Lawrence Inhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells Cancer Res., May 15, 2008; 68(10): 3803 - 3809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells Cancer Res., March 1, 2008; 68(5): 1471 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Re and J. L. Cook The Basis of an Intracrine Pharmacology J. Clin. Pharmacol., March 1, 2008; 48(3): 344 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kumar ErbB-Dependent Signaling as a Determinant of Trastuzumab Resistance Clin. Cancer Res., August 15, 2007; 13(16): 4657 - 4659. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
